600276 恒瑞医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入24,408,7635.26%31,629,41627,984,60522,819,78521,275,271
减:营业总成本17,294,4962.24%23,093,09821,008,00118,214,15317,747,084
    其中:营业成本3,225,7930.95%4,362,6563,848,1773,525,2483,486,639
               财务费用(116,288)-65.09%(406,945)(572,732)(478,390)(470,867)
               资产减值损失(88,695)552.20%(86,914)(32,538)(107,217)(146,684)
公允价值变动收益803,620721.69%173,574108,631(58,257)76,503
投资收益(107,830)164.14%(80,185)4,279(49,157)387,365
    其中:对联营企业和合营企业的投资收益(133,695)140.89%(97,143)(21,581)(72,696)(62,996)
营业利润7,993,89420.67%8,990,0037,490,6324,909,9054,111,960
利润总额7,728,63020.53%8,707,6267,169,6904,667,1103,968,492
减:所得税费用805,47623.58%990,623832,695389,289153,351
净利润6,923,15420.19%7,717,0026,336,9954,277,8213,815,142
减:非控股权益(250)-102.76%5,947468(24,615)(91,233)
股东净利润6,923,40420.38%7,711,0556,336,5274,302,4363,906,375

市场价值指针
每股收益 (元) *1.05017.98%1.1901.0000.6800.610
每股派息 (元) *----0.2000.2000.2000.160
每股净资产 (元) *10.06712.29%9.2327.1366.3445.929
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容